Brain Research Center Amsterdam B.V.
- Address
- lock Available on a paid plan
Alzheimer’s Disease Research
At Brain Research Center Amsterdam B.V., a major share of the clinical research focuses on Nervous System Diseases, especially Alzheimer’s disease and related cognitive disorders. These studies are designed to test new therapies, track disease-related biomarkers, and better understand how to slow memory and thinking decline.
- Early and mild to moderate Alzheimer’s disease
- Dominantly inherited Alzheimer disease and early-onset forms
- Biomarker and cognition-focused studies for disease progression
The research includes efforts to improve treatment effectiveness and identify measurable signs of brain change that may support earlier and more precise care.
Parkinson’s Disease Studies
The site also runs trials in Parkinson’s disease, reflecting its strong focus on neurology and movement-related disorders. These studies aim to evaluate whether new treatments can help slow symptom worsening and support daily functioning in people living with early-stage disease.
- Early Parkinson’s disease
- Movement and functional outcomes
- Testing potential disease-modifying therapies
This work helps explore whether emerging therapies can improve long-term disease control and quality of life.
Cardiovascular Disease Research
Alongside brain-focused studies, the center participates in trials on cardiovascular diseases, including heart failure, hypertension, and broader cardiovascular disease risk. These trials are intended to assess whether new treatment approaches can reduce serious heart-related events and improve prevention.
- Prevention of heart failure
- Type 2 diabetes with cardiovascular risk
- Reducing cardiovascular death and related complications
The research supports better strategies for patients with overlapping metabolic and heart conditions.
Mental Health and Cognitive Symptoms
Clinical trials at this Amsterdam site also cover Psychiatry and Psychology, with a focus on major depressive disorder and cognitive symptoms linked to brain disease. These studies are aimed at evaluating new options that may improve mood, thinking, and everyday functioning.
- Major depressive disorder
- Cognitive and global functioning outcomes
- Assessing safety and benefit of new adjunctive treatments
This area adds an important mental health dimension to the center’s broader neurological research portfolio.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 37 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
- 1F. Hoffmann-La Roche AG3active
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG5trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Brain Research Center Amsterdam B.V.
lock Showing 1 of 33 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer's Disease | Denali Therapeutics Inc. | Phase I | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 37 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Florbetaben (18F) | 4 | Unknown | 2023-09-28 | 2025-11-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.